Please Wait.....
Report
Global Severe Acne Vulgaris Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-15 I 147 Pages I EMR Inc.
Global Severe Acne Vulgaris Treatment Market Report and Forecast 2023-2031
Global Severe Acne Vulgaris Treatment Market Outlook
The global severe acne vulgaris treatment market growth can be attributed to the increasing prevalence of severe acne vulgaris, the development of novel therapies, and the rising demand for effective treatment options. The prevalence of acne vulgaris is likely to grow at a CAGR of 1.73% in the forecast period of 2023-2031.
Severe Acne Vulgaris Treatment Market: Introduction
Acne vulgaris is a common skin disorder that affects approximately 9.4% of the global population. Severe acne vulgaris is a more severe form of the condition, characterized by deep, painful nodules and cysts. The treatment of severe acne vulgaris typically involves a combination of topical and oral medications, including retinoids, antibiotics, and hormonal therapies. In severe cases, isotretinoin may be prescribed, although this medication carries significant side effects and requires close monitoring.
The report by Expert Market Research provides a comprehensive analysis of the severe acne vulgaris treatment market, including market size, growth, and trends. The report covers the market for severe acne vulgaris treatment, including drugs and therapies used for the treatment of the condition.
Severe Acne Vulgaris Epidemiology
Severe acne vulgaris is a prevalent condition, affecting millions of people worldwide. The condition is more common in adolescents and young adults, although it can affect individuals of all ages. Severe acne vulgaris can cause significant physical and psychological distress and can have a negative impact on an individual's quality of life.
The treatment of severe acne vulgaris typically involves a combination of topical and oral medications, including retinoids, antibiotics, and hormonal therapies. In severe cases, isotretinoin may be prescribed, although this medication carries significant side effects and requires close monitoring. Other treatment options for severe acne vulgaris include chemical peels, laser therapy, and photodynamic therapy.
As the global population continues to grow and the prevalence of severe acne vulgaris rises, the demand for effective treatment options is expected to increase. This is expected to drive the growth of the severe acne vulgaris treatment market, as healthcare providers seek new and innovative therapies to manage this debilitating condition.
Severe Acne Vulgaris Treatment Market Segmentations
The market can be categorised into drugs, type, treatment method, age group, distribution channel, treatment channel, and region.
Market Breakup by Drugs
- Prescription Medicines
- Over-the-Counter Medicines
Market Breakup by Type
- Non-Inflammatory Acne
- Inflammatory Acne
Market Breakup by Treatment Method
- Systemic Therapy
- Hormonal Therapy
o Oral Contraceptive
o Spironolactone
o Cyproterone Acetate
o Flutamide
- Topical Antibiotics
o Erythromycin
o Clindamycin
o Clarithromycin
o Azithromycin
o Nadifloxacin
- Topical Retinoids
o Adapalene
o Tazarotene
o Tretinoin
o Isotretinoin
o Metretinide
o Retinaldehyde
o Beta-Retinoyl Glucuronide
- Physical Treatment
o Lesion Removal
o Phototherapy
- Topical Combination Therapy
o Chemical Peeling
- Glycolic Acids Peel
- Salicylic Acid Peel
o Pulsed Dye Laser Treatment
o Others
Market Breakup by Age Group
- 10-17 years
- 18-40 years
- 40-65 years
- 65 and Above
Market Breakup by Distribution Channel
- Derma Clinics
- Pharmacy
- E-Commerce
Market Breakup by Treatment Channel
- Public
- Private
Severe Acne Vulgaris Treatment Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Severe Acne Vulgaris Treatment Market Scenario
The market is expected to experience steady growth during the forecast period of 2023-2031. The key drivers of the market include the increasing prevalence of severe acne vulgaris, the development of novel therapies, and the rise in healthcare expenditure. However, the availability of over-the-counter acne treatments and the potential side effects associated with prescription medications are likely to hinder the growth of the market.
North America dominates the severe acne vulgaris treatment market, followed by Europe and the Asia Pacific. The high prevalence of severe acne vulgaris in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for severe acne vulgaris treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the condition and the rising healthcare expenditure in the region.
The market for severe acne vulgaris treatment can be categorized into various segments, including treatment type, distribution channel, and end-user. The most used treatment types for severe acne vulgaris include topical medications and oral medications. In terms of distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Key Players in the Global Severe Acne Vulgaris Treatment Market
The report gives an in-depth analysis of the key players involved in the severe acne vulgaris treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- AbbVie, Inc (Allergen)
- Botanix Pharmaceuticals Ltd.
- Galderma S.A.
- Bausch Health Companies Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson Services Inc.
- Almirall S.A.
- Hospira, Inc.
- Viatris (Mylan N.V.)
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Perrigo Company Plc.
- Boston Scientific Corporation (Lumenis)
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Severe Acne Vulgaris Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Severe Acne Vulgaris Treatment Market
8.1 Global Severe Acne Vulgaris Treatment Market Overview
8.2 Global Severe Acne Vulgaris Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Severe Acne Vulgaris Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Severe Acne Vulgaris Treatment Market Forecast Value (2023-2031)
8.3 Global Severe Acne Vulgaris Treatment Market by Drugs
8.3.1 Market Overview
8.3.1.1 Prescription Medicines
8.3.1.2 Over-the-Counter Medicines
8.4 Global Severe Acne Vulgaris Treatment Market by Type
8.4.1 Market Overview
8.4.1.1 Non-Inflammatory Acne
8.4.1.2 Inflammatory Acne
8.5 Global Severe Acne Vulgaris Treatment Market by Treatment Method
8.5.1 Market Overview
8.5.1.1 Systemic Therapy
8.5.1.2 Hormonal Therapy
8.5.1.2.1 Oral Contraceptive
8.5.1.2.2 Spironolactone
8.5.1.2.3 Cyproterone Acetate
8.5.1.2.4 Flutamide
8.5.1.3 Topical Antibiotics
8.5.1.3.1 Erythromycin
8.5.1.3.2 Clindamycin
8.5.1.3.3 Clarithromycin
8.5.1.3.4 Azithromycin
8.5.1.3.5 Nadifloxacin
8.5.1.4 Topical Retinoids
8.5.1.4.1 Adapalene
8.5.1.4.2 Tazarotene
8.5.1.4.3 Tretinoin
8.5.1.4.4 Isotretinoin
8.5.1.4.5 Metretinide
8.5.1.4.6 Retinaldehyde
8.5.1.4.7 Beta-Retinoyl Glucuronide
8.5.1.5 Physical Treatment
8.5.1.5.1 Lesion Removal
8.5.1.5.2 Phototherapy
8.5.1.6 Topical Combination Therapy
8.5.1.7 Chemical Peeling
8.5.1.7.1 Glycolic Acids Peel
8.5.1.7.2 Salicylic Acid Peel
8.5.1.8 Pulsed Dye Laser Treatment
8.5.1.9 Others
8.6 Global Severe Acne Vulgaris Treatment Market by Age Group
8.6.1 Market Overview
8.6.1.1 10-17 years
8.6.1.2 18-40 years
8.6.1.3 40-65 years
8.6.1.4 65 and Above
8.7 Global Severe Acne Vulgaris Treatment Market by Distribution Channel
8.7.1 Market Overview
8.7.1.1 Derma Clinics
8.7.1.2 Pharmacy
8.7.1.3 E-Commerce
8.8 Global Severe Acne Vulgaris Treatment Market by Treatment Channel
8.8.1 Public
8.8.2 Private
8.9 Global Severe Acne Vulgaris Treatment Market by Region
8.9.1 Market Overview
8.9.1.1 North America
8.9.1.2 Europe
8.9.1.3 Asia Pacific
8.9.1.4 Latin America
8.9.1.5 Middle East and Africa
9 North America Severe Acne Vulgaris Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Severe Acne Vulgaris Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Severe Acne Vulgaris Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Severe Acne Vulgaris Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Severe Acne Vulgaris Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Severe Acne Vulgaris Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 AbbVie, Inc (Allergen)
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Botanix Pharmaceuticals Ltd.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Galderma S.A.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Bausch Health Companies Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 GlaxoSmithKline Plc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Johnson & Johnson Services Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Almirall S.A.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Hospira, Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Viatris (Mylan N.V.)
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Sun Pharmaceutical Industries Ltd.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Pfizer Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Teva Pharmaceutical Industries Ltd.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Bayer AG
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
15.14 Perrigo Company Plc.
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
15.14.5 Certifications
15.15 Boston Scientific Corporation (Lumenis)
15.15.1 Company Overview
15.15.2 Product Portfolio
15.15.3 Demographic Reach and Achievements
15.15.4 Mergers and Acquisitions
15.15.5 Certifications
16 Severe Acne Vulgaris Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security